Business Wire

TX-MAVENIR

11.2.2020 14:02:08 CET | Business Wire | Press release

Share
Mavenir and MUGLER Collaborate to Deliver Mavenir End-to-End 5G Private Networks in Germany

Mavenir, the industry's only end-to-end cloud-native 4G/5G network software provider for CSPs, has announced collaboration and joint go-to-market with MUGLER, a leading and well-established neutral system integrator for telco networks in Germany, to deliver Mavenir’s end-to-end 5G solutions including 5G vRAN, 5G Core & Digital Enablement Platform to the German Enterprise & Industry Market, enabled by the German Government’s Private Networks initiative and the allocation of spectrum for private enterprise and industry use.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005394/en/

Mavenir will offer its full portfolio of 4G and 5G solutions for the German Private Networks market to address the needs of Enterprises, Industries and Service Providers. Mugler will act as go to market partner for Mavenir as well as a value-added reseller including systems integration and local operation and support. In addition, Mugler has secured a private networks license from BNetzA (the German frequency regulator) and will deploy an end-to-end 5G system on its own campus at Oberlungwitz (Saxony, Germany). This network will be used for advanced enterprise use cases such as AGVs for logistics, AR/VR, IoT, Video, Broadcast and Secure Communications for Mugler’s enterprise needs, as well as a showcase and testbed for end customers.

Jointly, the companies will address the growing business opportunity for private networks for the Industry, Media, Health, Public Authorities and Service Provider segments and customers.

A Comprehensive Private Networks Solution for Enterprises and Industries

The German Government’s private networks initiative has allocated spectrum in the 3.7-3.8 GHz band for enterprises and industries to build their own mobile networks in environments such as campuses, venues, offices, factories and ports etc.

Mavenir’s OpenRAN vRAN encompasses 4G and 5G radio access, and the disaggregated RAN approach extends virtualization to the edge of the network and provides strategic differentiation by enabling multisource Remote Radio Units (RRUs) to interwork with the virtualized, containerized, Cloud Base Band software over ethernet Fronthaul (FH), using the O-RAN open interface overcoming the traditional constraints of the proprietary walled garden specifications used by the other traditional equipment vendors.

Mavenir’s 5G Core solution , based on cloud-native principles, can be retrofitted on EPCs and encompasses all the major 5G core elements, and these functions are implemented as micro-services in containers. The Mavenir 5G Core also combines 4G EPC functionality and offers a ‘Converged Mobile Core’ solution that supports both 4G and 5G subscribers. In addition, the Mavenir 5G Core supports all Standalone (SA) and Non-Standalone (NSA) options.

Mavenir’s Digital Enablement platform allows Private Network operators to create a seamless way of abstracting out the complexity of the underlying network, and create a digital app store for enterprise and industry applications – thereby empowering an ecosystem of developers, service providers, technology companies, enterprises and industries to create applications to power digitalization with 5G.

This end-to-end 5G system, based on cloud-first and open architecture principles, is highly suited to address both mass scale private enterprise use cases as well as bespoke high-end use cases for advanced industries. The solution can be delivered as on-prem “network-in-a-box”, cloud-based “Network-as-a-Service” or Hybrid models.

With Mugler’s advanced services those networks can be deployed as turn-key solutions anywhere in Germany and beyond. Furthermore, Mugler’s Telco mplete® - Process covers the whole lifecycle of telco networks and infrastructure with all managed services, including end to end network design and planning, systems integration, deployment, support, maintenance, repair and field service 365/24/7.

Quotes

“As 5G use cases are emerging, together with Mugler, we are bringing our 4G/5G virtualized portfolio of solutions to the German market for quick and easy deployments,” said Aniruddho Basu, Mavenir’s SVP/GM of Emerging Business. “Mavenir’s OpenRAN vRAN and Converged Mobile Core solutions provide a cost-efficient approach to addressing the rising need for private networks for enterprises, industries and service providers.”

“Private networks will revolutionize a lot of industries. They will have an enormous leverage for digitization,” said Fabian Berger, Mugler’s Director Local Networks. “To deploy and operate those networks flexibly and cost effectively, OpenRAN and virtualized networks are up-and-coming. We see Mavenir as a strong partner to be able to quickly develop and deploy customized private networks for different industries and customers.”

About Mavenir

Mavenir is the industry's only end-to-end, cloud-native Network Software Provider focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC, and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.

We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve webscale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. Learn more at www.mavenir.com

About Mugler

Mugler is a medium-sized company based and mainly active in Germany. Since the foundation of our company in 1990, we have become a well-established and leading service provider and neutral system integrator for telecommunication networks and infrastructure in Germany. Today 320 employees implement our slogan “from idea to network” with our full-service Telco mplete®-Process, covering the complete lifecycle of all kinds of telecommunication infrastructure including network design and planning, systems integration, deployment, maintenance, operation and support.

With this and our long lasting know-how we are able to provide and maintain sustainable networks to all kinds of customers, from the large German CSPs (mobile and fixed) to public authorities, as well as large and smaller companies.

Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.

Copyright © 2020 Mavenir Systems, Inc. All Rights Reserved.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye